Navigation Links
Helix BioPharma Completes Definitive GLP Toxicology Studies With L-DOS47 and is Making Final Preparations for its Planned Phase I/II Clinical Study IND/CTA Submissions
Date:10/12/2010

AURORA, Ontario, Oct. 12 /PRNewswire/ -- Helix BioPharma Corp. (TSX, NYSE Amex, FSE: HBP) today announced that it has completed its definitive GLP, rodent and primate, repeat-dose toxicology studies with L-DOS47.   These studies demonstrated a good safety profile in an expanded number of rodent and primate test animals, building upon Helix's positive findings from its preliminary non-GLP toxicology studies.  

The Company plans to conduct a Phase I study in the U.S. in patients with refractory solid tumors and a  Phase I/II, multi-arm safety and preliminary efficacy study in patients with stage III/IV non-small cell lung cancer in Poland.  It intends to use the findings from its GLP toxicology studies to complete the necessary protocol designs and other supportive documentation, as final steps in preparing its U.S. Phase I IND and its Polish Phase I/II CTA dossiers.  As a result of some delays in completing its GLP toxicology studies, Helix now expects these IND/CTA submissions to be made in its second rather than its first quarter of fiscal 2011.  

"We are very pleased to reach this important clinic-enabling milestone in our L-DOS47 development program," said John Docherty, Helix president and COO.  "Having completed these studies, Helix believes it now has a sufficient preclinical pharmacology and toxicology database to support human clinical testing with this important new drug candidate.  Helix is committed to completing these submissions as soon as possible, as it is no longer waiting for any further preclinical study findings before doing so."

About Helix BioPharma Corp.Helix BioPharma Corp. is a biopharmaceutical company focused on cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies.  Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new dr
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
2. Helix BioPharma Announces $11.4 Million Private Placement
3. Helix Biopharma Closes $11.4 Million Private Placement
4. Helix BioPharma Corp. Announces Fiscal 2008 Results
5. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission
6. Helix BioPharma Announces Q1 2009 Financial Results
7. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
8. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
9. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
10. Helix BioPharma Announces Q2 2009 Financial Results
11. Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 2015  BioNano Genomics, Inc., the leader in genome ... as chief commercial officer. Salyer has more than 20 ... in life sciences. At BioNano, Salyer will oversee the ... platform to assemble a comprehensive view of complex genomes ... 32 institutions located in the United States ...
(Date:3/26/2015)... Neogen Corporation (NASDAQ: NEOG ) announced today that ... 2015, which ended Feb. 28, increased 13% to $7,454,000, ... share in the current quarter were $0.20, compared to ... 17% over prior year to $24,142,000, or $0.65 per ... the same period a year ago. Revenues ...
(Date:3/26/2015)... Texas (PRWEB) March 26, 2015 ReliantHeart, ... technologies, and Transonic, a supplier of precision transit-time flow ... that will greatly improve the efficiency of the ... enable LVAD patients to experience greater mobility and peace ... with the miniature flow board, will draw 1/6th of ...
(Date:3/26/2015)... Ale Gicqueau, Founder and President of Clinovo, will co-present ... Technology, on “ Conducting Postmarket Registries - Rationale and ... and Exhibition on April 25th through April 28th in ... presentation, Ale Gicqueau and Victor Chen will discuss the ... requirements and resources to conduct the registry, as well ...
Breaking Biology Technology:BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 2Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 3
... 23 BioRelix, pioneers in the discovery and ... Dalton Medicinal Chemistry have jointly announced an ... and agreement to discover and develop new therapeutics.Dalton ... the design and synthesis of new classes of ...
... new study examining the aftereffects of a chlorine gas disaster ... insight into what to expect and how to prepare emergency ... potentially deadly gas. The study is now available in the ... Medicine . , "This is one of the largest ...
... 20 Isolagen(TM), Inc. (Amex: ILE ) ... notice from the Amex (the "Exchange") notifying the Company ... the Exchange,s Company Guide (the "Company Guide"). Specifically, the ... are so substantial in relation to its overall operations ...
Cached Biology Technology:BioRelix and Dalton Medicinal Chemistry Expand and Renew Research Agreement to Capitalize on Riboswitches 2New study examines effects of Graniteville, S.C., chlorine gas disaster 2New study examines effects of Graniteville, S.C., chlorine gas disaster 3Isolagen, Inc. Receives Notification Letter from Amex 2Isolagen, Inc. Receives Notification Letter from Amex 3Isolagen, Inc. Receives Notification Letter from Amex 4
(Date:3/17/2015)... MedNet Solutions , a global ... management systems, is pleased to announce that company ... in Clinical Trials Southeast conference – March 24-25 ... forum for MedNet to showcase iMedNet , ... eClinical technology platform. We strongly encourage ...
(Date:3/16/2015)... HANOVER, Germany , March 16, 2015 /PRNewswire/ ... DERMALOG Identification Systems GmbH will present groundbreaking innovations ... Hanover, Germany . ... DERMALOG,s latest biometric innovation is well at ... the next generation e-gate made in ...
(Date:3/12/2015)... , March 12, 2015 ... standardized identity and access management (IAM) solution for ... schedule. With Beta System,s new IAM package, customers ... practices gleaned from multiple IAM implementations across different ... software as well as any necessary services and ...
Breaking Biology News(10 mins):Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2
... found a surprising link between brain iron levels ... ranging from autism to major depression., Appearing in ... Sciences this week, the study by Randy ... of a powerful in silico approach for discovering ...
... Wegener Institute for Polar and Marine Research in ... expedition LOHAFEX". Independent scientific and legal reviews sought ... and the Federal Ministry for the Environment, Nature ... fertilisation experiment LOHAFEX is neither against environmental standards ...
... Drug Administration is reconsidering the use of stimulants to ... to support a University of Houston professor,s theory that ... order. Richard A. Bond, professor of ... (UHCOP), has been investigating whether beta-2 adrenoreceptor antagonist drugs ...
Cached Biology News:Researchers iron out new role for serotonin 2Polarstern expedition 'LOHAFEX' can be conducted 2Polarstern expedition 'LOHAFEX' can be conducted 3New asthma research opposes current drug treatment, says UH prof 2New asthma research opposes current drug treatment, says UH prof 3New asthma research opposes current drug treatment, says UH prof 4
7G10 anti-Fasciclin III...
Rabbit polyclonal to Nck alpha ( Abpromise for all tested applications). entrezGeneID: 4690 SwissProtID: P16333...
Rabbit polyclonal to P5 ( Abpromise for all tested applications). entrezGeneID: 10954 SwissProtID: Q14554...
Rabbit polyclonal to ZA20D3 ( Abpromise for all tested applications). entrezGeneID: 54469 SwissProtID: Q6FIF0...
Biology Products: